MX2009010243A - Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6. - Google Patents
Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6.Info
- Publication number
- MX2009010243A MX2009010243A MX2009010243A MX2009010243A MX2009010243A MX 2009010243 A MX2009010243 A MX 2009010243A MX 2009010243 A MX2009010243 A MX 2009010243A MX 2009010243 A MX2009010243 A MX 2009010243A MX 2009010243 A MX2009010243 A MX 2009010243A
- Authority
- MX
- Mexico
- Prior art keywords
- serotonin
- receptor
- respond
- modulation
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se relaciona con nuevos compuesto de quinolina. Los compuestos poseen propiedades terapéuticas valiosas y son apropiados, en particular, para tratar enfermedades que responden a la modulación del receptor de serotonina 5-HT6. La fórmula (I) en donde R es una porción de la fórmula (R) donde A, R1 a R4 son según se define en las reivindicaciones y en la descripción, n es 0, 1 ó 2; mes 0, 1, 2 ó 3; Ra, Rb se seleccionan independientemente entre el grupo que consiste en halógeno, CN, C1-C4-alquilo, C1-C4-haloalquilo, C1-C4-alcoxi, C1-C4-haloalcoxi, C(O)Raa, C(O)NRCCRbb y NRccRbb X es CH2, C(O), S, S(O) o S(O)2 que está situado en la posición 3 ó 4 del anillo quinolina; Ar es un radical Ar1, Ar2-Ar3 o Ar2-O-Ar3, donde Ar1, Ar2 y Ar3 se seleccionan independientemente entre sí, del grupo que consiste en arilo o heteroarilo donde las unidades arilo o heteroarilo pueden no estar sustituidas o pueden contener 1, 2, 3 sustituyentes Rx, donde Rx es como se define en las reivindicaciones y en la descripción; y sales de adición de ácido fisiológicamente toleradas y los N-óxidos de las mismas. (ver fórmula (I)).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07104806 | 2007-03-23 | ||
| PCT/EP2008/053387 WO2008116831A1 (en) | 2007-03-23 | 2008-03-20 | Quinoline compounds suitable for treating didorders that respond to modulation of the serotonin 5-ht6 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009010243A true MX2009010243A (es) | 2009-12-14 |
Family
ID=39620293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009010243A MX2009010243A (es) | 2007-03-23 | 2008-03-20 | Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8242102B2 (es) |
| EP (1) | EP2139880B1 (es) |
| JP (1) | JP5538907B2 (es) |
| KR (1) | KR20090128426A (es) |
| CN (1) | CN101679351B (es) |
| AR (1) | AR068381A1 (es) |
| AT (1) | ATE524456T1 (es) |
| AU (1) | AU2008231787A1 (es) |
| BR (1) | BRPI0809081A2 (es) |
| CA (1) | CA2681030C (es) |
| CO (1) | CO6230989A2 (es) |
| CR (1) | CR11039A (es) |
| DO (1) | DOP2009000228A (es) |
| EC (1) | ECSP099651A (es) |
| ES (1) | ES2373617T3 (es) |
| HK (1) | HK1139933A1 (es) |
| IL (1) | IL201105A0 (es) |
| MX (1) | MX2009010243A (es) |
| NZ (1) | NZ579735A (es) |
| PE (1) | PE20091187A1 (es) |
| RU (1) | RU2009139073A (es) |
| TW (1) | TW200940524A (es) |
| UA (1) | UA97837C2 (es) |
| UY (1) | UY31326A (es) |
| WO (1) | WO2008116831A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130343993A1 (en) * | 2012-01-06 | 2013-12-26 | Abbvie Inc. | Radiolabeled 5-ht6 ligands |
| US20140120036A1 (en) * | 2012-01-06 | 2014-05-01 | Abbvie Inc. | Radiolabeled 5-ht6 ligands |
| AR106515A1 (es) * | 2015-10-29 | 2018-01-24 | Bayer Cropscience Ag | Sililfenoxiheterociclos trisustituidos y análogos |
| US10160744B2 (en) * | 2016-03-14 | 2018-12-25 | AbbVie Deutschland GmbH & Co. KG | Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-HT6 receptor |
| CN109053524A (zh) * | 2018-09-11 | 2018-12-21 | 山东谛爱生物技术有限公司 | 一种N-Boc-3-羟基氮杂环丁烷的制备方法 |
| CN109503449A (zh) * | 2018-12-17 | 2019-03-22 | 天津药明康德新药开发有限公司 | 一种3-硝基吖丁啶-1-甲酸叔丁酯的合成方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA02002220A (es) * | 1999-09-02 | 2002-09-02 | Wakunaga Pharma Co Ltd | Derivados de acido quinolincarboxilico o su sal. |
| JP2003277416A (ja) * | 2002-03-22 | 2003-10-02 | Daiyanitorikkusu Kk | 糖類を含むアクリルアミド水溶液 |
| NZ535239A (en) * | 2002-03-27 | 2008-03-28 | Glaxo Group Ltd | Quinoline derivatives and their use as 5-HT6 ligands |
| AU2002243097A1 (en) | 2002-04-03 | 2003-10-13 | Hyundai Pharm. Ind. Co., Ltd. | Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same |
| JP4390698B2 (ja) | 2002-06-05 | 2009-12-24 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｎｓ障害の処置のための５−ｈｔ６レセプターモジュレーターとしての１−スルホニル−４−アミノアルコキシインドール誘導体 |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| US7227023B2 (en) | 2003-04-30 | 2007-06-05 | Wyeth | Quinoline 3-amino chroman derivatives |
| GB0321473D0 (en) | 2003-09-12 | 2003-10-15 | Glaxo Group Ltd | Novel compounds |
| GB0411421D0 (en) * | 2004-05-21 | 2004-06-23 | Glaxo Group Ltd | Novel compounds |
| KR20080030058A (ko) * | 2005-07-27 | 2008-04-03 | 에프. 호프만-라 로슈 아게 | 5-ｈｔ6 조절인자로서 4-아릴옥시 퀴놀린 유도체 |
| GB0519765D0 (en) * | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel compounds |
| EP2120950B1 (en) | 2007-03-21 | 2012-07-04 | Glaxo Group Limited | Use of quinoline derivatives in the treatment of pain |
-
2008
- 2008-03-20 BR BRPI0809081A patent/BRPI0809081A2/pt not_active IP Right Cessation
- 2008-03-20 UA UAA200910698A patent/UA97837C2/ru unknown
- 2008-03-20 AU AU2008231787A patent/AU2008231787A1/en not_active Abandoned
- 2008-03-20 RU RU2009139073/04A patent/RU2009139073A/ru not_active Application Discontinuation
- 2008-03-20 KR KR1020097019918A patent/KR20090128426A/ko not_active Application Discontinuation
- 2008-03-20 CN CN200880017192.XA patent/CN101679351B/zh not_active Expired - Fee Related
- 2008-03-20 NZ NZ579735A patent/NZ579735A/en not_active IP Right Cessation
- 2008-03-20 CA CA2681030A patent/CA2681030C/en not_active Expired - Fee Related
- 2008-03-20 JP JP2009554034A patent/JP5538907B2/ja not_active Expired - Fee Related
- 2008-03-20 EP EP08735447A patent/EP2139880B1/en active Active
- 2008-03-20 AT AT08735447T patent/ATE524456T1/de not_active IP Right Cessation
- 2008-03-20 MX MX2009010243A patent/MX2009010243A/es active IP Right Grant
- 2008-03-20 WO PCT/EP2008/053387 patent/WO2008116831A1/en active Application Filing
- 2008-03-20 ES ES08735447T patent/ES2373617T3/es active Active
- 2008-03-23 US US12/532,407 patent/US8242102B2/en active Active
- 2008-09-02 TW TW097133636A patent/TW200940524A/zh unknown
- 2008-09-08 UY UY0001031326A patent/UY31326A/es not_active Application Discontinuation
- 2008-09-08 PE PE2008001568A patent/PE20091187A1/es not_active Application Discontinuation
- 2008-09-08 AR ARP080103894A patent/AR068381A1/es not_active Application Discontinuation
-
2009
- 2009-09-22 DO DO2009000228A patent/DOP2009000228A/es unknown
- 2009-09-22 IL IL201105A patent/IL201105A0/en unknown
- 2009-09-22 CO CO09103181A patent/CO6230989A2/es not_active Application Discontinuation
- 2009-09-23 EC EC2009009651A patent/ECSP099651A/es unknown
- 2009-09-23 CR CR11039A patent/CR11039A/es unknown
-
2010
- 2010-07-02 HK HK10106465.1A patent/HK1139933A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2681030C (en) | 2015-01-13 |
| ECSP099651A (es) | 2009-10-30 |
| DOP2009000228A (es) | 2009-10-15 |
| UA97837C2 (ru) | 2012-03-26 |
| EP2139880A1 (en) | 2010-01-06 |
| PE20091187A1 (es) | 2009-09-06 |
| HK1139933A1 (en) | 2010-09-30 |
| IL201105A0 (en) | 2010-05-17 |
| WO2008116831A1 (en) | 2008-10-02 |
| CA2681030A1 (en) | 2008-10-02 |
| RU2009139073A (ru) | 2011-04-27 |
| CN101679351A (zh) | 2010-03-24 |
| CN101679351B (zh) | 2015-01-07 |
| ES2373617T3 (es) | 2012-02-07 |
| ATE524456T1 (de) | 2011-09-15 |
| CO6230989A2 (es) | 2010-12-20 |
| NZ579735A (en) | 2012-02-24 |
| UY31326A (es) | 2009-11-10 |
| TW200940524A (en) | 2009-10-01 |
| JP5538907B2 (ja) | 2014-07-02 |
| JP2010521520A (ja) | 2010-06-24 |
| EP2139880B1 (en) | 2011-09-14 |
| CR11039A (es) | 2010-02-09 |
| KR20090128426A (ko) | 2009-12-15 |
| US8242102B2 (en) | 2012-08-14 |
| US20110009380A1 (en) | 2011-01-13 |
| BRPI0809081A2 (pt) | 2019-09-24 |
| AR068381A1 (es) | 2009-11-11 |
| AU2008231787A1 (en) | 2008-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200505907A (en) | Piperidine-benzenesulfonamide derivatives | |
| UA99626C2 (ru) | Соединения хинолина, пригодные для лечения нарушений, реагирующих на модуляцию рецептора 5-нт6 серотонина | |
| EA201290260A1 (ru) | Бензимидазол-имидазольные производные | |
| EA200501585A1 (ru) | Производные азетидинкарбоксамида и их применение при лечении нарушений, опосредованных св1 рецепторами | |
| MX2009008465A (es) | Nuevas 2-aminooxazolinas como ligandos de taar1. | |
| TW200745066A (en) | Novel PTP1B inhibitors | |
| CY1112011T1 (el) | Παραγωγα αζαδικυκλο (3.1.0) εξανιου χρησιμα ως ρυθμιστες υποδοχεων d3 ντοπαμινης | |
| MX2009010243A (es) | Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6. | |
| MX2009013591A (es) | Proceso para la preparacion de pirazoles. | |
| MX2009010790A (es) | Derivados de heteroarilo biciclico fusionados. | |
| TW200833675A (en) | Nicotinamide derivatives | |
| CZ302359B6 (cs) | Triazolové slouceniny a jejich použití | |
| BRPI0519794A2 (pt) | derivados de [4-(heteroaril)piperazin-1-il]-(fenil 2,5-substituìdo)metanona como inibidores de transportador de glicina 1 (glyt-1) para o tratamento de distúrbios neurológicos e neuropsiquiátricos | |
| MX2010005649A (es) | Compuestos novedosos como ligandos del receptor canabinoide y sus usos. | |
| MY153719A (en) | Prokineticin 1 receptor antagonists | |
| TW200716566A (en) | Prokineticin 2 receptor antagonists | |
| PT1622880E (pt) | ''di-hidroquinazolinas substituídas com propriedades antivirais'' | |
| ATE524181T1 (de) | Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen | |
| MX2010008361A (es) | Derivados de arilamida oxazepinopirimidona sustituidos. | |
| JP2010522157A (ja) | 潜在的制癌剤としての新規アントラニル酸誘導体及びその調製方法 | |
| DE502005008351D1 (de) | Chinolinderivat, dessen verwendung, herstellung und dieses enthaltendes arzneimittel | |
| MEP11508A (en) | Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof | |
| MXPA05011198A (es) | Derivados de oxifenilo aromaticos y de sulfanilfenilo aromaticos. | |
| DK1745010T3 (da) | Substituerede cyklohexyl-1,4-diaminderivater | |
| KR20200038473A (ko) | 히스톤 데아세틸라제 1 및 2 (hdac1-2)의 선택적인 저해제로서 새로운 헤테로아릴 아미드 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| GB | Transfer or rights |